News on immunoassay systems and applications.
The firms will focus on developing and implementing biomarker-based immunoassay diagnostics for kidney injury.
UBS granted Agilent a Buy rating and a $92 price target, and Qiagen a Neutral rating with a $42 price target.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.
Regional Medical Laboratory, a commercial reference lab, is using the Alinity next-gen immunoassay system in the face of growing test volumes and a shortage of trained labor.
